This trial is worth considering for patients with newly diagnosed Glioblastoma - if they happen to live in the NY City area. Enrollment must begin before radiation starts.
Interesting trial about to open for DIPG. This drug, OKN-007 recently reported good results for recurrent Glioblastoma, with an average survival of about 20 months compared to historical average of about 8 months. The Musella Foundation gave one of the first grants to get this started, back in 2013! I wish them luck and I will let you know when the trial opens.
Look at episode 2 which focuses on Dr Alfredo Quinones-Hinojosa, a neurosurgeon at the Mayo Clinic in Florida. Interesting story of how he became a neurosurgeon and it shows an awake surgery for a brain tumor!
They will be testing their drug, paxalisib, in combination with Onc-201 in patients with DIPG. Sounds very interesting!
This trial for recurrent malignant glioma is now available in 3 major centers in Texas. It is a new way to target radiation to the tumor. Early trial results reported promising extension of survival for recurrent glioblastoma.
Of course using the word cure is way too early but this sounds like an interesting treatment.
Although this article is about lung cancer patients, it applies even more to brain tumor patients. The cancer takes so much from us already. This article says over 70% of female lung cancer patients have sexual dysfunction. I would bet the number for brain tumor patients is higher since we also deal with so many other issues. The good news is much of it can be treated. The big impediment is awareness. Sex is not something we like to talk about and takes a back seat to issues involving the tumor. However, it has a huge impact on quality of life. If you are having problems, talk to your doctor or nurse about it.
I mentioned this before but it is very important so sending it again. If your pathology report says you have any of these mutations, you are eligible for the program. They are: MAPK, KRAS, NRAS, HRAS, BRAF, MEK, and/or ERK
This is in mice, but probably would work the same way in people. Might be a perfect use for Avastin - which also reduces brain swelling. Perhaps it could eliminate or at least reduce the amount of Dexamethasone used while undergoing immunotherapy. Also points to the need for other treatments for brain swelling like Xerecept, which did well in clinical trials but then just disappeared. At that time, the reduction in Dexamethasone dosage was not seen as important enough to continue development of the drug. Now it is.
SNO is the Society Of Neuro-Oncology's Annual Scientific meeting. Follow the link below to see my thoughts on the highlights and to discuss them!
I posted this a few weeks ago but at that time they had some paperwork delays and couldn't enroll patients. Now they can! This is for anyone with a grade 3 or grade 4 malignant tumor that needs a surgery. If you need a surgery anyway, it is worth considering adding a treatment that could help stop the tumor from coming back quickly. There is only 1 participating center right now, Moffitt Cancer Center in Tampa Florida, but one of my favorite neurosurgeons, Michael Vogelbaum, MD, PhD will be doing the surgery.
From our good friends at UCLA. Should be very informative! Now that it is virtual, everyone should watch it.
This is considered the standard of care for the treatment of brain tumors in the USA. It doesn't include GammaTile since although approved and worthwhile are not available everywhere yet - hopefully they will be added to the next version!
These guidelines say for Glioblastoma, that Clinical Trials should be considered first, then if not possible, they now include Optune and Temodar along with radiation and surgery as the recommended treatment.
(In a small study) The local control rate at 1 year for newly diagnosed metastatic tumors was 100% and for recurrent tumors it was 80%. Patients still died from the primary cancer but this seems to be an effective way to hit those brain mets.
This was one of the highlights of this week SNO conference. The concept is elegant read about it on the company's website. Impressive early results.
This was a lot of fun. Thanks to Novocure for setting it up!
This is preclinical work but fascinating new approach. CRISPR is a gene editing tool which can be programmed to cut out any gene. This first attempt is proof of the principle that it can be directed to tumors inside a live animal. The possibilities are endless, perhaps starting with other genes in the tumor like the MGMT gene which creates a repair enzyme which offers resistance to Temodar, or to genes in the entire body such as any of the oncogenes like the BRCA genes which increase chances of many types of cancer.
This is another one of the highlights from the SNO conference this week. Exciting results in recurrent Glioblastoma. Median overall survival of 12.5 months compared to historic controls of 7.2 months. Another elegant solution - see their website for details! When we get some of these treatments approved and can start combining them, we will see major breakthroughs!
I went to the presentation on this and it was impressive. RNL is a nanoliposomal formulation that delivered directly to where it is needed in the brain via convection enhanced delivery. It releases radiation in a much higher dose to the tumor bed than external beam radiation does, and a smaller dose to the surrounding tissue. It is still very early of course but the concept is elegant and early data looks good. They reported that patients who previously used Avastin did not do as well as those who never used Avastin, but in the presentation it was explained that the convection enhanced delivery of the patients who used Avastin was difficult and only reached about 1/2 of the tumor coverage that those who never had Avastin achieved. Perhaps this is a technical problem that can be solved so it helps both groups.
This should allow for the more complete removal of these tumors!